The safety and efficacy of TACE combined with apatinib on patients with advanced hepatocellular carcinoma: a retrospective study. Issue 3 (4th March 2019)

• Record Type: Journal Article
• Authors: Yang, Zeran; Chen, Guang; Cui, Ye; Xiao, Guowen; Su, Tianhao; Yu, Jianan; Zhang, Zhiyuan; Han, Yanjing; Yang, Kailan; Jin, Long
• Is Part Of: Cancer biology & therapy. Volume 20:Issue 3(2019)
• Page Start: 321
• Page End: 327
• Publication Date: 2019-03-04
• Subjects: hepatocellular carcinoma -- apatinib -- transarterial chemoembolization -- targeted therapy -- combination therapy, vascular endothelial growth factor receptor-2 -- angiogenesis; 616.99406
• DOI: 10.1080/15384047.2018.1529099
• Languages: English
• ISSNs: 1538-4047

Abstract

ABSTRACT: As a novel vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor (VEGFR2-TKI), apatinib has a certain anti-tumor effect for a variety of solid tumors. The present study evaluates its efficacy and safety in advanced hepatocellular carcinoma (HCC). In this study, 47 patients with advanced HCC were included. TACE monotherapy group included 22 patients that responded to TACE, while the group that received TACE and apatinib included 25 patients that progressed on TACE and were able to receive apatinib off label. Median overall survival (OS) was significantly improved in the apatinib plus TACE group compared with the TACE group. Similarly, apatinib in combination with TACE significantly prolonged median progression-free survival (PFS) compared with TACE monotherapy. Furthermore, there was a significant difference between combination therapy and monotherapy in both Barcelona clinic liver cancer (BCLC) B and BCLC C group. The combination therapy had a dramatic effect on OS and PFS for patients at both BCLC B and BCLC C level. The most common clinically adverse events of apatinib plus TACE group were fatigue, weight loss, hypertension, hand-foot syndrome and anorexia, which were manageable and tolerable. The efficacy analysis showed that there was no significant association of survival benefit with age, gender, Eastern Cooperative Oncology Group (ECOG) performance status, hypertension and hand-foot syndrome. Patients with macrovascular invasion and extrahepatic invasion showed worse survival benefits. In conclusion, apatinib combined with TACE revealed certain survival benefits for HCC patients who experienced progression following TACE, which can provide a promising strategy for HCC treatment.